Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chloramphenicol + dexamethasone is a fixed-dose combination drug consisting of two active ingredients: chloramphenicol, a broad-spectrum bacteriostatic antibiotic, and dexamethasone, a potent synthetic corticosteroid. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes, thereby preventing the growth of both gram-positive and gram-negative bacteria. Dexamethasone exerts anti-inflammatory and immunosuppressive effects by inhibiting multiple inflammatory cytokines and mediators such as prostaglandins. This combination is primarily used topically (eye drops, ear drops, ointments) for the treatment of ocular or otic infections where inflammation coexists with or increases the risk for bacterial infection—such as conjunctivitis, keratitis, blepharitis, corneal ulcers (eye), otitis externa or media (ear), post-operative eye inflammation/infection prevention. The dual action addresses both infection control and symptomatic relief from inflammation[2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloramphenicol + dexamethasone.